Harrow agrees to acquire US rights to Novartis’ ophthalmic products
Pharmaceutical Technology
DECEMBER 14, 2022
Harrow has signed a binding agreement to acquire exclusive US commercial rights to five ophthalmic products of Novartis. These products, namely, Ilevro, Vigamox, Maxidex, Nevanac and Triesence, have received approval from the Food and Drug Administration (FDA). Outside of the US region, Novartis will have sole rights to the products.
Let's personalize your content